Kangpu Biopharma

Kangpu Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative small molecule therapeutics for cancer, autoimmune diseases, and inflammatory disorders. The company leverages its proprietary Neo-substrate Modulating Proteolysis (NSMP) and X-Synergy technology platforms to develop a robust pipeline of molecular glue protein degraders. These therapies are designed to harness the body's natural protein degradation machinery to eliminate disease-causing proteins that were previously considered undruggable. Kangpu's lead programs, including KPG-818 and KPG-121, are currently in Phase 2 clinical trials for indications such as systemic lupus erythematosus and prostate cancer. Headquartered in Shanghai with operations in the United States, the company is supported by leading venture capital investors.